Inside the 92nd AUA Meeting: A Deep Dive into High-Risk Non-Muscle Invasive Bladder Cancer - Kriti Mittal
October 13, 2023
During the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) multidisciplinary symposium held at the 2023 Meeting of the New England Section of the AUA Kriti Mittal opens the symposium organized in partnership with the Bladder Cancer Advocacy Network and supported by Pfizer, the event features a panel of experts from various institutions.
This video is part of the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer multidisciplinary symposium held at the 92nd Meeting of the New England Section of the AUA, organized in partnership with the Bladder Cancer Advocacy Network and supported by Pfizer, the event featured a panel of experts from various institutions.
Biographies:
Kriti Mittal, MD, MS, Medical Oncologist, University of Massachusetts
This video is part of the State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer multidisciplinary symposium held at the 92nd Meeting of the New England Section of the AUA, organized in partnership with the Bladder Cancer Advocacy Network and supported by Pfizer, the event featured a panel of experts from various institutions.
Biographies:
Kriti Mittal, MD, MS, Medical Oncologist, University of Massachusetts
Related Content:
View the Symposium Video Channel: State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer
The Complex Case of a 46-Year-Old Smoker with High-Grade T1 Bladder Cancer - Jennifer Yates, Matthew Mossanen, & Kent Mouw
In the Wake of BCG Shortages: A Look at Ongoing Clinical Trials and Future Therapies for Bladder Cancer - Jennifer Yates, Lydia Saravis, & Matthew Mossanen
View the Symposium Video Channel: State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer
The Complex Case of a 46-Year-Old Smoker with High-Grade T1 Bladder Cancer - Jennifer Yates, Matthew Mossanen, & Kent Mouw
In the Wake of BCG Shortages: A Look at Ongoing Clinical Trials and Future Therapies for Bladder Cancer - Jennifer Yates, Lydia Saravis, & Matthew Mossanen
Read the Full Video Transcript
Kriti Mittal: Thank you, everyone, for being here bright and early for this multidisciplinary symposium at the 92nd Meeting of the New England Section of the AUA. Thanks again to the organizing committee for having us here. Today, we're going to talk about state-of-the-art management of high-risk non-muscle invasive bladder cancer.
By way of introduction, my name is Kriti Mittal. I'm a Medical Oncologist at the University of Massachusetts. The symposium is being organized in partnership with the Bladder Cancer Advocacy Network. It is supported by an educational grant from Pfizer. Highlights from this talk will be posted in a question-and-answer format on the Mednet, which is an online community for expert answers for real-life clinical scenarios. A video recording of the symposium will also be posted on UroToday.
We are delighted to have with us Ms. Lydia Saravis from BCAN, who will provide some patient perspective on non-muscle invasive bladder cancer today. Thank you, Lydia, for being here. And our panelists: Dr. Matthew Mossanen from Dana-Farber, Brigham and Women's; Dr. Jennifer Yates from the University of Massachusetts; Dr. Kent Mouw from Dana-Farber Brigham's; Dr. Guru Sonpavde from AdventHealth; and Ms. Laura Wood from Cleveland Clinic. Thank you.
These are our disclosures. And with that, I would like to invite Dr. Mossanen, who'll be presenting the first few cases. We are going to reserve questions until the end.
Kriti Mittal: Thank you, everyone, for being here bright and early for this multidisciplinary symposium at the 92nd Meeting of the New England Section of the AUA. Thanks again to the organizing committee for having us here. Today, we're going to talk about state-of-the-art management of high-risk non-muscle invasive bladder cancer.
By way of introduction, my name is Kriti Mittal. I'm a Medical Oncologist at the University of Massachusetts. The symposium is being organized in partnership with the Bladder Cancer Advocacy Network. It is supported by an educational grant from Pfizer. Highlights from this talk will be posted in a question-and-answer format on the Mednet, which is an online community for expert answers for real-life clinical scenarios. A video recording of the symposium will also be posted on UroToday.
We are delighted to have with us Ms. Lydia Saravis from BCAN, who will provide some patient perspective on non-muscle invasive bladder cancer today. Thank you, Lydia, for being here. And our panelists: Dr. Matthew Mossanen from Dana-Farber, Brigham and Women's; Dr. Jennifer Yates from the University of Massachusetts; Dr. Kent Mouw from Dana-Farber Brigham's; Dr. Guru Sonpavde from AdventHealth; and Ms. Laura Wood from Cleveland Clinic. Thank you.
These are our disclosures. And with that, I would like to invite Dr. Mossanen, who'll be presenting the first few cases. We are going to reserve questions until the end.